Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2022 Mar 14;39(5):2281. doi: 10.1007/s12325-022-02082-9

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era

Stefan Schreiber 1, Shomron Ben-Horin 2, Rieke Alten 3, René Westhovens 4, Laurent Peyrin-Biroulet 5,6, Silvio Danese 7, Toshifumi Hibi 8, Ken Takeuchi 9, Fernando Magro 10,11,12, Yoorim An 13, Dong-Hyeon Kim 13, SangWook Yoon 13, Walter Reinisch 14,✉
PMCID: PMC8918596  PMID: 35287234

Correction to: Adv Ther 10.1007/s12325-021-01990-6

In the original article, a few errors were introduced by the publisher during the typesetting process. The Graphical Abstract has been updated and a few minor formatting corrections have been made.

The original article has been corrected.

Articles from Advances in Therapy are provided here courtesy of Nature Publishing Group

RESOURCES